Thyroid Cancer pp 239-249 | Cite as

Diagnosis of Medullary Thyroid Cancer


Medullary thyroid carcinoma (MTC) is a rare calcitonin (CT)-secreting tumor of the parafollicular or C cells of the thyroid. As the C cells originate from the embryonic neural crest, MTC often has the clinical and histological features of neuroendocrine tumors. It accounts for 8%–12% of all thyroid carcinomas and occurs in both sporadic and hereditary forms. The discovery of an MTC in a patient has several diagnostic implications involving a specific strategy: preoperative evaluation of the extent of the disease, classification of MTC as sporadic or hereditary by DNA testing, and screening for associated endocrinopathies in hereditary MTC.


Thyroid Nodule Medullary Thyroid Carcinoma Multiple Endocrine Neoplasia Type Medullary Thyroid Multiple Endocrine Neoplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15: 1613–1619PubMedGoogle Scholar
  2. 2.
    Berndt I, Reuter M, Sailer B, Frank-Raue K, Groth P, Grußendorf M, Raue F, Ritter MM, Höppner W (1998) A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83: 770–774PubMedCrossRefGoogle Scholar
  3. 3.
    Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tourniaire J, Lenoir GM, Romeo G (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10: 2415–2419PubMedGoogle Scholar
  4. 4.
    Cohen R, Campos JM, Salaün C, Heshmati M, Kraimps JL, Proye C, Sarfati E, Henry JF, Niccoli-Sire P, Modigliani E (2000) Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 85: 905–918CrossRefGoogle Scholar
  5. 5.
    Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2: 851–856PubMedCrossRefGoogle Scholar
  6. 6.
    Dottorini M, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Cancer 77: 1556–1565PubMedCrossRefGoogle Scholar
  7. 7.
    Eng C (1996) The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung’s disease. N Engl J Med 335: 943–951PubMedCrossRefGoogle Scholar
  8. 8.
    Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE,Waterfield MD, Ponder BAJ (1995) A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10: 509–513Google Scholar
  9. 9.
    Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel H-KP, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xu F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zendenius J, Nordenskjöld M, Komminoth P, Hendy G, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 276: 1575–1579Google Scholar
  10. 10.
    Frank-Raue K, Höppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F, and the German Medullary Thyroid Carcinoma Group (1996) Mutations of the RET proto-oncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 81: 1780–1783Google Scholar
  11. 11.
    Frank-Raue K, Kratt T, Höppner W, Buhr H, Ziegler R, Raue F (1996) Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2–relevance of specific mutations in the RET proto-oncogene. Eur J Endocr 135: 222–225CrossRefGoogle Scholar
  12. 12.
    Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P, Bongarzone I, Greco A, Astakhova L, Butti MG, Demidchik EP, Pacini F, Pierotti MA (1995) Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 55: 5617–5620PubMedGoogle Scholar
  13. 13.
    Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA (1989) Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 111: 802–806PubMedGoogle Scholar
  14. 14.
    Giuffrida D, Gharib H (1998) Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 9: 695–701PubMedCrossRefGoogle Scholar
  15. 15.
    Grauer A, Raue F, Ziegler R (1998) Clinical usefulness of a new chemoluminescent two-site immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes 106: 353–359PubMedCrossRefGoogle Scholar
  16. 16.
    Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G (1990) PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557–563PubMedCrossRefGoogle Scholar
  17. 17.
    Heshmati HM, Gharib H, van Heerden JA, Sizemore GW (1997) Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 103: 60–69PubMedCrossRefGoogle Scholar
  18. 18.
    Moers AM, Lansvater RM, Schaap C, Jansen-Schillhorn von Veen JM, de Valk IAJ, Blijham GH, Höppner JWM, Vroom TM, van Amstel HKP, Lips CJM (1996) Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101: 635–641Google Scholar
  19. 19.
    Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gager RF, Takai SI, Noll WW, Fink M (1995) Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238: 343–346PubMedCrossRefGoogle Scholar
  20. 20.
    O’Riordian D, O’Brien T, Crotty TB, Garib H, Grant CS, van Heerden JA (1995) Multiple endocrine neoplasia type 2b: more than an endocrine disorder. Surgery 118: 936–942CrossRefGoogle Scholar
  21. 21.
    Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A (1994) Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 78: 826–829PubMedCrossRefGoogle Scholar
  22. 22.
    Raue F (1998) German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbeck’s Arch Surg 383: 334–336PubMedCrossRefGoogle Scholar
  23. 23.
    Raue F, Grauer A (1994) Determination of tumor markers in diagnosis and follow-up of patients with medullary thyroid carcinoma. Exp Clin Endocrinol 102 (Suppl 2): 67–73Google Scholar
  24. 24.
    Raue F, Kotzerke J, Reinwein D, Schröder S, Röher HD, Deckart H, Höfer R, Ritter M, Seif F, Buhr HJ, Beyer J, Schober O, Becker W, Neumann H, Calvi J, Winter J, Vogt H, and the German Medullary Thyroid Carcinoma Study Group (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German medullary thyroid carcinoma register. Clin Invest 71: 7–12Google Scholar
  25. 25.
    Raue F, Frank-Raue K, Grauer A (1994) Multiple endocrine neoplasia type 2, clinical features and screening. Endocrinol Metab Clin North Am 23: 137–156PubMedGoogle Scholar
  26. 26.
    Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, LLenas LF, Niederle B (1995) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238: 369–373PubMedCrossRefGoogle Scholar
  27. 27.
    Rieu M, Lame M-C, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod J-L, Fombeur JP (1995) Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol 42: 453–460CrossRefGoogle Scholar
  28. 28.
    Russo D, Chiefari E, Meringolo D, Bianchi D, Bellanova B, Filetti S (1997) A case of metastatic medullary thyroid carcinoma: early identification before surgery of an RET proto-oncogene somatic mutation in fine needle aspirate specimens. J Clin Endocrinol Metab 82: 3378–3382PubMedCrossRefGoogle Scholar
  29. 29.
    Santoro M, Carlomagno F, Romano A, et al. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 267: 381–383PubMedCrossRefGoogle Scholar
  30. 30.
    Schröder S, Holl K, Padberg BC (1992) Pathology of sporadic and hereditary medullary thyroid carcinoma. Recent Results Cancer Res 125: 19–45PubMedCrossRefGoogle Scholar
  31. 31.
    Scopsi L, Sampietro G, Boracchi P, Del Bo R, Gullo M, Placucci M, Pilotti S (1996) Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. Cancer 78: 2173–2183PubMedCrossRefGoogle Scholar
  32. 32.
    Smith DP, Houghton C, Ponder BA (1997) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15: 1213–1217PubMedCrossRefGoogle Scholar
  33. 33.
    Vasen, HF, van der Feltz M, Raue F, Nieuwenhuyzen Kruseman A, Koppeschaar HPF, Pieters G, Seif f J, Blum WF, Lips CJM (1992) The natural course of multiple endocrine neoplasia type 2 b. Arch Intern Med 152: 1250–1252PubMedCrossRefGoogle Scholar
  34. 34.
    Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhäusl A, Niederle B (1997) Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 82: 1589–1593PubMedCrossRefGoogle Scholar
  35. 35.
    Wohllk N, Cote GJ, Bugalho MMJ, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards S, Gagel RS (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endorinol Metab 81: 3740–3745CrossRefGoogle Scholar
  36. 36.
    Zedenius J, Wallin G, Hamberger B, Nordenskjöld M, Weber G, Larsson C (1994) Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC’s. Hum Mol Genet 3: 1259–1262PubMedCrossRefGoogle Scholar
  37. 37.
    Zedenius J, Larsson C, Bergholm U, Bovée J, Svensson A, Hallergren B, Grimelius L, Bäckdahl M, Weber G, Wallin G (1995) Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma. J Clin Endocr Metab 80: 3088–3090PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • F. Raue

There are no affiliations available

Personalised recommendations